R Erber1, A Hartmann2, M W Beckmann3, A Mackensen4, A Kremer4, H Reimann4, H Hübner3, A Hein3, M P Lux3, S Jud3, L Häberle3, P Gaß3, B Volz3, R Schulz-Wendtland5, M Rübner3, P A Fasching3. 1. Pathologisches Institut, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Deutschland. Ramona.Erber@uk-erlangen.de. 2. Pathologisches Institut, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Deutschland. 3. Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Deutschland. 4. Medizinische Klinik 5, Hämatologie und Internistische Onkologie, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Deutschland. 5. Radiologisches Institut/Gynäkologische Radiologie, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Deutschland.
Abstract
BACKGROUND: The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy. OBJECTIVES: Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study. METHODS: Illustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study. RESULTS: pCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC. CONCLUSIONS: First results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue.
BACKGROUND: The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy. OBJECTIVES: Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study. METHODS: Illustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study. RESULTS: pCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC. CONCLUSIONS: First results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue.
Entities:
Keywords:
Breast neoplasms; Immunotherapy; Neoadjuvant therapy; Neoplasm antigens; Tumor-infiltrating lymphocytes
Authors: Franziska M Wuerfel; Hanna Huebner; Lothar Häberle; Paul Gass; Alexander Hein; Sebastian M Jud; Carolin C Hack; Marius Wunderle; Rüdiger Schulz-Wendtland; Ramona Erber; Arndt Hartmann; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Matthias Ruebner Journal: Sci Rep Date: 2020-09-25 Impact factor: 4.379
Authors: Hannah Reimann; Andrew Nguyen; J Zachary Sanborn; Charles J Vaske; Stephen C Benz; Kayvan Niazi; Shahrooz Rabizadeh; Patricia Spilman; Andreas Mackensen; Matthias Ruebner; Alexander Hein; Matthias W Beckmann; Edith D van der Meijden; Judith Bausenwein; Sascha Kretschmann; Marieke Griffioen; Jeffrey Schlom; James L Gulley; Karin L Lee; Duane H Hamilton; Patrick Soon-Shiong; Peter A Fasching; Anita N Kremer Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751